Shunichiro Iwasawa
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.
Journal: Investigational new drugs
Published: December 11, 2024
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Journal: Cancer research communications
Published: April 08, 2024
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 26, 2024
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients.
Journal: Advances in therapy
Published: January 30, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients.
Journal: Advances in therapy
Published: January 30, 2024
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL.
Journal: JTO clinical and research reports
Published: January 17, 2024
Venous Stent Placement for Malignant Vena Cava Syndrome in a Patient with Liposarcoma.
Journal: The American journal of case reports
Published: January 11, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).
Journal: JTO clinical and research reports
Published: October 03, 2022
Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.
Journal: Clinical lung cancer
Published: May 30, 2022
Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel.
Journal: Drug design, development and therapy
Published: November 12, 2021
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 17, 2021
Last Updated: 09/26/2026